Telerobotic surgery is moving from isolated demonstrations toward broader clinical and regulatory development, with SS Innovations International Inc. (NASDAQ: SSII) emerging as a notable player in the field. The company reported 195 robotic telesurgeries using its SSi Mantra system as of September 28, 2026, including cardiac procedures and long-distance operations. This milestone underscores the potential for remote surgery to extend specialized care to underserved regions and reduce travel burdens for patients.
In an interview with MedTech Dive, SS Innovations CEO Dr. Sudhir Srivastava, a cardiac surgeon, explained that robotic surgery is inherently a form of teleoperation. He noted that the central technical question is how much distance can be introduced without compromising responsiveness. The MedTech Dive article, titled “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s development and the regulatory and infrastructure questions surrounding remote surgery. It highlighted SS Innovations International (NASDAQ: SSII) alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL).
The company’s installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures reached 14,503. SSi Mantra has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand the system into additional international markets. These regulatory milestones could significantly broaden the system’s addressable market and accelerate adoption in high-income countries.
For healthcare providers, the growth of telerobotic surgery could mean greater access to expert surgeons regardless of geographic barriers. For patients, it may translate into shorter wait times and reduced travel for complex procedures. For the medical device industry, SS Innovations’ progress adds competitive pressure to develop robust telesurgery platforms that meet stringent regulatory standards. The company’s newsroom is available at https://ibn.fm/SSII.
MissionIR, a specialized communications platform, distributes updates on SS Innovations through its network. As part of the Dynamic Brand Portfolio @ IBN, MissionIR leverages wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. This broad reach helps ensure that developments in telerobotic surgery reach investors, healthcare professionals, and the public.
As remote procedures gain ground, SS Innovations’ accumulating clinical experience and regulatory pursuits will be key indicators of whether telesurgery becomes a mainstream option. The outcomes of its FDA and CE marking efforts could influence not only the company’s trajectory but also the broader adoption of telerobotic systems worldwide.
